LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $253,700 | -16.3% | 215,000 | 0.0% | 0.01% | -35.7% |
| Q2 2023 | $303,150 | -6.0% | 215,000 | 0.0% | 0.01% | -22.2% |
| Q1 2023 | $322,500 | +28.2% | 215,000 | 0.0% | 0.02% | +5.9% |
| Q4 2022 | $251,550 | +3.5% | 215,000 | 0.0% | 0.02% | -29.2% |
| Q3 2022 | $243,000 | -28.5% | 215,000 | 0.0% | 0.02% | -33.3% |
| Q2 2022 | $340,000 | +2.7% | 215,000 | 0.0% | 0.04% | -16.3% |
| Q1 2022 | $331,000 | -37.2% | 215,000 | 0.0% | 0.04% | -38.6% |
| Q4 2021 | $527,000 | – | 215,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
| Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
| Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
| Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
| DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
| Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
| Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
| XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
| Ergoteles LLC | 490,895 | $555,000 | 0.02% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |